Sales and production of the sauces made by First and Last Bakery have been suspended to ensure compliance with regulations, ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

The U.S. FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, ...

An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...

Shares of Biohaven fell more than 40% on Wednesday after the U.S. Food and Drug Administration declined to approve its experimental treatment for a rare brain disorder.

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to M2T-CD33 (LTI-214) for the treatment of ...

The FDA announced it will relax certain rules for approving low-cost versions of some high-priced medications.

The FDA plans to eliminate comparative clinical study requirements that currently add $24 million and up to eight years to ...

The U.S. Food and Drug Administration announced plans to reduce the amount of fluoride present in ingestible children’s products.

Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just days after he was placed on administrative leave while federal officials ...